BioCardia completes enrollment in low dose cohort in CardiALLO Phase I/II trial
BioCardia (BCDA) announced completion of enrollment and dosing in the low dose cohort in its CardiALLO Allogeneic Mesenchymal Cell Therapy ...
Corbus Pharmaceuticals announces data from its US, UK study of CRB-701
Corbus Pharmaceuticals (CRBP) announced that data from its US and UK conducted first-in-human dose escalation clinical study of CRB-701 is ...
Phase raises $13M to speed up the UX design process with its no-code platform
UX and UI designers work closely with engineers throughout product development to build and implement design concepts and ...
Blueprint Medicines Corporation: Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results
Achieved $479.0 million in AYVAKIT® (avapritinib) global net product revenues in 2024, including $144.1 million in the fourth quarter -- -- Anticipate global AYVAKIT ...